Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis

Therapeutic Advances in Musculoskeletal Disease

Volumn 4, Issue 6, 2012, Pages 387-397

  Yokota, Shumpei ^a   Tanaka, Toshio ^b   Kishimoto, Tadamitsu ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

a humanized anti interleukin 6 receptor antibody; Interleukin 6; systemic juvenile idiopathic arthritis; tocilizumab

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 6; PLACEBO; TOCILIZUMAB;

ADVERSE OUTCOME; BACTERIAL ARTHRITIS; CHICKENPOX; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CYTOKINE PRODUCTION; DEHYDRATION; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM PERFORATION; EAR INFECTION; ECZEMA; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEART AMYLOIDOSIS; HUMAN; INFUSION RELATED REACTION; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; MONONUCLEOSIS; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PUSTULE; REVIEW; RHINOPHARYNGITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 84874207708     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12455960     Document Type: Review

References (64)

1. Al-Shanti N. Stewart C. (2011) Inhibitory effects of IL-6 on IGF-1 activity in skeletal myoblasts could be mediated by the activation of SOCS-3. J Cell Biochem 113: 923–933.
2. Beukelman T. Patkar N. Saag K. Tolleson-Rinehart S. Cron R. DeWitt E. et al. (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63: 465–482.
3. Boulanger M. Chow D. Brevnova E. Garcia K. (2003) Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300: 2101–2104.
4. Bradham C. Qian T. Streetz K. Trautwein C. Brenner D. Lemasters J. (1998) The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 18: 6353–6364.
5. de Benedetti F. Alonzi T. Moretta A. Lazzaro D. Costa P. Poli V. et al. (1997 a) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-1: a model for stunted growth in children with chronic inflammation. J Clin Invest 99: 643–650.
6. de Benedetti F. Brunner H. Ruperto N. Calvo N. Cuttica I. Malattia R. et al. (2010) Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum 62(Suppl. 10): 1434.
7. de Benedetti F. Brunner H. Ruperto N. Schneider R. Woo P. Burgos-Vargas R. et al. (2011) Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data. Pediat Rheumatol 9(Suppl. 1): P164.
8. de Benedetti F. Martini A. (2005) Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 52: 687–693.
9. de Benedetti F. Massa M. Pignatti P. Albani S. Novick D. Martini A. (1994) Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile idiopathic arthritis. J Clin Invest 93: 2114–2119.
10. de Benedetti F. Massa M. Robbioni P. Ravelli A. Burgio G. Martini A. (1991) Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34: 1158–1163.
11. de Benedetti F. Pignatti P. Gerloni V. Massa M. Sartirana P. Caporali R. et al. (1997 b) Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 24: 1403–1409.
12. Fishman D. Faulds G. Jeffery R. Mohamed-Ali V. Yudkin J. Humphries S. et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369–1376.
13. Ganz T. Nemeth E. (2011) Hepcidin and disorders of iron metabolism. Annu Rev Med 62: 347–360.
14. Gattorno M. Piccini A. Lasiglie D. Tassi S. Brisca G. Carta S. et al. (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58: 1505–1515.
15. Giannini E. Ruperto N. Ravelli A. Lovell D. Felson D. Martini A. (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40: 1202–1209.
16. Grom A. Mellins E. (2010) Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 22: 561–566.
17. Hagihara K. Nishikawa T. Sugamata Y. Song J. Isobe T. Taga T. et al. (2005) Essential role of STAT 3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells 10: 1051–1063.
18. Heinrich P. Castell V. Andus T. (1990) Interleukin-6 and the acute phase response. Biochem J 265: 621–636.
19. Herlin T. (2009) Tocilizumab: the evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evid 4: 181–189.
20. Hibi M. Murakami M. Saito M. Hirano T. Taga T. Kishimoto T. (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63: 1149–1157.
21. Imagawa T. Yokota S. Mori M. Miyamae T. Takei S. Imanaka H. et al. (2011) Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 22: 109–115.
22. Inaba Y. Ozawa R. Imagawa T. Mori M. Hara Y. Miyamae T. et al. (2011) Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis 70: 1693–1695.
23. Ishibashi T. Kimura H. Shikama Y. Uchida T. Kariyone S. Hirano T. et al. (1989) Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241–1244.
24. Kimura A. Kishimoto T. (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40: 1830–1835.
25. Kishimoto T. (1989) The biology of interleukin-6. Blood 74: 1–10.
26. Kishimoto T. (2005) Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1–21.
27. Kishimoto T. Taga T. Akira S. (1994) Cytokine signal transduction. Cell 76: 253–262.
28. Korn T. Bettelli E. Oukka M. Kuchroo V.K. (2009) IL-17 and Th 17 cells. Annu Rev Immunol 27: 485–517.
29. Kotake S. Sato K. Kim K. Takahashi N. Udagawa N. Nakamura I. et al. (1996) Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11: 88–95.
30. Lang B. Schneider R. Reilly B. Silverman E. Laxer R. (1995) Radiographic features of systemic onset juvenile idiopathic arthritis. J Rheumatol 22: 168–173.
31. Levi M. Keller T. van Gorp E. ten Cate H. (2003) Infection and inflammation and the coagulation system. Cardiovasc Res 60:26–39.
32. Lin Y. Wang C. Gershwin M. Chiang B. (2011) The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis. Autoimmun Rev 10: 482–489.
33. Lurati A. Teruzzi B. Salmaso A. et al. (2005) Macrophage activation syndromeduring anti-IL-1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis. Paed Rheumatol Online J 3: 79–85.
34. Mellins E. Macaubas C. Grom A. (2011) Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more question. Nat Rev Rheumatol 7: 416–426.
35. Muller K. Herner E. Stagg A. Bendtzen K. Woo P. (1998) Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Rheumatology (Oxford) 37: 562–569.
36. Murakami M. Hibi M. Nakagawa N. Nakagawa T. Yasukawa K. Yamanishi K. et al. (1993) IL-6-induced homodimerization of gp 130 and associated activation of a tyrosine kinase. Science 260: 1808–1810.
37. Nakajima S. Naruto T. Miyamae T. Imagawa T. Mori M. Nishimaki S. et al. (2009 a) Interleukin-6 inhibits early differentiation of ATDC 5 chondrogenic progenitor cells. Cytokine 47: 91–97.
38. Nakajima S. Naruto T. Miyamae T. Imagawa T. Mori M. Nishimaki S. et al. (2009 b) Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 19: 42–46.
39. Nemeth E. Rivera S. Gabayan V. Keller C. Taudorf S. Pedersen B. et al. (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271–1276.
40. Nigrovic P. Mannion M. Prince F. Zeft A. Ravinovich C. van Rossum M. et al. (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis-report of forty-six patients from an international multicenter series. Arthritis Rheum 63: 545–555.
41. Nishikawa T. Hagihara K. Serada S. Isobe T. Matsumura A. Song J. et al. (2008) Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 180: 3492–3501.
42. Nistala K. Wedderburn L. (2009) Th 17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology 48: 602–606.
43. Obici L. Perfetti V. Palladini G. Moratti R. Merlini G. (2005) Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 1753: 11–22.
44. Ogilvie E. Fife M. Thompson S. Twine N. Moroldo M. Fisher S. et al. (2003) The –174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 48: 3202–3206.
45. Palmqvist P. Persson E. Conaway H. Lerner U. (2002) IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappaB ligand, osteoprotegerin, and receptor activation of NF-kappaB in mouse calvariae. J Immunol 169: 3353–3362.
46. Petty R. Southwood T. Manners P. Baum J. Glass D. Goldenberg J. et al. (2004) International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 31: 390–392.
47. Pignatti P. Vivarelli M. Meazza C. Rizzolo M. Martini A. de Benedetti F. (2001) Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol 28: 1670–1676.
48. Prakken B. Albani S. Martini A. (2011) Juvenile idiopathic arthritis. Lancet 377: 2138–2149.
49. Ramanan A. Grom A. (2005) Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) 44: 1350–1353.
50. Ramanan A. Schneider R. (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30:401–403.
51. Rooney M. David J. Symons J. Di Giovine F. Varsani H. Woo P. (1995) Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 34: 454–460.
52. Sato K. Tsuchiya M. Saldanha J. Koishihara Y. Oshugi Y. Kishimoto T. et al. (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851–856.
53. Sawhney S. Woo P. Murray K. (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85: 421–426.
54. Still G. (1941) On a form of chronic joint disease in children. Arch Dis Child 16: 156–165.
55. Tanaka T. Narazaki M. Kishimoto T. (2012) Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol 52: 199–219.
56. Tran T. Eubanks S. Schaffer K. Zhou C. Linder M. (1997) Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 90: 4979–4986.
57. Woo P. Wilkinson N. Prieur A. Southwood T. Leone V. Livermore P. et al. (2005) Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 7: R1281–R1288.
58. Yamasaki K. Taga T. Hirata Y. Yawata H. Kawanishi Y. Seed B. et al. (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241: 825–828.
59. Yokota S. Miyamae T. Imagawa T. Iwata N. Katakura S. Mori M. (2004) Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis. Mod Rheumatol 14: 12–17.
60. Yokota S. Imagawa T. Miyamae T. Kasai K. Mori M. Nishimoto N. et al. (2008 b) Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis. Pediat Rheumatol 6(Suppl. 1): S1.
61. Yokota S. Imagawa T. Mori M. Miyamae T. Aihara Y. Takei S. et al. (2008 a) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371: 998–1006.
62. Yokota S. Imagawa T. Takei S. Murata T. Tomiita M. Itoh Y. et al. (2011) Guideline on using tocilizumab for juvenile idiopathic arthritis. Mod Rheumatol 2011: 20 May (Epub ahead of print).
63. Yokota S. Kishimoto T. (2010) Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol 6: 735–743.
64. Yokota S. Miyamae T. Imagawa T. Iwata N. Katakura S. Mori M. et al. (2005) Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 52: 818–825.